Former Merck KGaA heavyweight joins EnteroBiotix as executive chairman

17 July 2023

Elmar Schnee (pictured above) has been named the new executive chairman of EnteroBiotix, a company that claims to be pioneering the future of modern medicine through microbiome-modulating therapeutics.

Mr Schnee succeeds Douglas Thomson, who will remain as a non-executive board member of the privately-held Scotland-based firm.

"His exceptional leadership skills and extensive industry experience will be instrumental in guiding EnteroBiotix as we advance our lead product and pipeline through clinical development"Bringing with him broad experience from the international pharmaceutical industry, Mr Schnee is expected to play a pivotal role in leading EnteroBiotix to deliver on its next phase of growth.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK